GlassScriptPhysician profile
Laura Tom
NPI 1053610832
$1,204.77
in general payments reported to CMS, 2019-2025
7 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.57 · 2020: $47.55 · 2021: $37.56 · 2022: $32.90 · 2023: $165 · 2024: $482 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726 · Long Term Medical Supply Or Device Loan: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.05 |
| Long Term Medical Supply Or Device Loan | $306.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $848.89 | 2020-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Baxter Healthcare | $155.02 | 2019-2023 | |
| Smith+Nephew, INC. | $66.08 | 2020-2021 | |
| Mentor Worldwide LLC | $53.80 | 2022-2023 | Mentor Cpx 2 Breast Tissue Expander |
| Covidien LP | $43.70 | 2019 | |
| Axogen | $24.57 | 2024 | Axoguard Nerve Cap, Axoguard Ha+ Nerve Protector, Axoguard Nerve Protector |
| Kerecis Limited | $12.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Tom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.